Danaher Corporation(DHR) Stock Research - Grey Stern Research
Loading...

Danaher Corporation (DHR) Stock Analysis

$238.36 (-1.46%)

DHR Financial Performance


Use the table below to view Danaher Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $238.36 -
52 Week Low $224.73 -
52 Week High $281.70 -
Market Cap $172.2 Billion 2/10
Gross Margin 30% 10/10
Profit Margin 24% 2/10
EBITDA margin 28% 2/10
Q3 - 2024 Revenue $3.4 Billion 2/10
Q3 - 2024 Earnings $818.0 Million 2/10
Q3 - 2024 Free Cash Flow $1.2 Million 2/10
Trailing 4 Quarters Revenue $18.7 Billion 2/10
Trailing 4 Quarters Earnings $3.9 Billion 2/10
Quarterly Earnings Growth -28% 9/10
Annual Earnings Growth -12% 9/10
Quarterly Revenue Growth -51% 10/10
Annual Revenue Growth -1% 3/10
Cash On Hand $2.6 Billion 2/10
Short Term Debt $1.2 Billion 2/10
Long Term Debt $16.3 Billion 2/10

Danaher Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Danaher Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 44.23 1/10
PS 9.20 1/10
PB 3.36 6/10
PC 65.54 4/10
Liabilities to Equity 0.57 8/10
ROA 0.05 6/10
ROE 0.08 9/10
Current Ratio 2.75 1/10
Quick Ratio 0.09 8/10
Long Term Debt to Equity 0.32 6/10
Debt to Equity 0.34 7/10
Burn Rate 19.47 1/10
Cash to Cap 0.02 6/10
CCR 1.49 3/10
EV to EBITDA 195.26 2/10
EV to Revenue 9.99 1/10

Company Details

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

CEO: Mr. Thomas Joyce

Website: https://www.danaher.com

Address: 2200 Pennsylvania Ave NW Ste 800w WASHINGTON, WASHINGTON DC

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Danaher Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Danaher Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Agilent Technologies, Inc. A $42.1 Billion
Thermo Fisher Scientific Inc. TMO $214.1 Billion
Illumina, Inc. ILMN $21.7 Billion
IDEXX Laboratories, Inc. IDXX $34.3 Billion
Waters Corporation WAT $24.0 Billion
Charles River Laboratories International, Inc. CRL $8.4 Billion
Mettler-Toledo International Inc. MTD $27.3 Billion
Invitae Corporation NVTA $5.4 Million
Guardant Health, Inc. GH $4.5 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
DHR Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 3.4 Billion $818.0 Million
Q2 2024 $ 5.7 Billion $907.0 Million
Q1 2024 $ 5.8 Billion $1.1 Billion
Q4 2023 $ 3.8 Billion $1.1 Billion
Q3 2023 $ 6.9 Billion $1.1 Billion
Q2 2023 $ 4.0 Billion $1.1 Billion
Q1 2023 $ 7.2 Billion $1.5 Billion
Q4 2022 $ 8.4 Billion $2.2 Billion

View All

DHR Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $2.6 Billion $80.6 Billion $17.5 Billion $51.3 Billion
Q2 2024 $2.4 Billion $78.6 Billion $18.2 Billion $49.9 Billion
Q1 2024 $7.0 Billion $83.4 Billion $19.3 Billion $53.4 Billion
Q4 2023 $5.9 Billion $84.5 Billion $18.4 Billion $53.5 Billion
Q3 2023 $12.3 Billion $87.7 Billion $22.1 Billion $52.4 Billion
Q2 2023 $8.6 Billion $84.9 Billion $19.9 Billion $51.7 Billion
Q1 2023 $7.4 Billion $85.0 Billion $19.8 Billion $51.5 Billion
Q4 2022 $6.0 Billion $84.4 Billion $19.7 Billion $50.1 Billion

View All

DHR Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.2 Billion -$298.0 Million -$1.5 Billion
Q2 2024 $1.1 Billion -$287.0 Million -$4.7 Billion
Q1 2024 $1.4 Billion -$291.0 Million $1.2 Billion
Q4 2023 $1.2 Billion -$434.0 Million -$6.2 Billion
Q3 2023 $1.3 Billion -$365.0 Million $3.7 Billion
Q2 2023 $1.6 Billion -$341.0 Million $1.2 Billion
Q1 2023 $1.7 Billion -$275.0 Million $1.4 Billion
Q4 2022 $2.2 Billion -$329.0 Million $845.0 Million

View All